Final Results

MedPal AI PLC (AIM: MPAL) has reported its final results for the year ending August 31, 2025, revealing a pre-tax loss of £4 million, a notable increase from a loss of £13,587 in the previous year. This shift marks the company's transition from a pre-revenue entity to a fully operational digital health and pharmacy services provider. The company successfully raised approximately £2 million during its AIM admission in August 2025 and subsequently secured an additional £2.54 million through various fundraising efforts. The post-year-end developments include the acquisition of assets from Universal Pharmacy Limited for £45,000, the launch of a 24/7 AI-powered National Distribution Centre, and a significant increase in dispensing efficiency, which has enabled pharmacy revenues to exceed £350,000 per month by dispensing over 70,000 items in December 2025 and January 2026.

The results reflect a strategic pivot towards vertical integration in the digital health sector, with MedPal AI establishing itself as a key player in the UK market. The acquisition of Universal Pharmacy's assets, including an NHS Distance Selling Pharmacy licence, and the opening of the National Distribution Centre in October 2025 are critical steps in enhancing operational capabilities. The company has also launched its retail pharmacy website, MedPal.clinic, and achieved a 30-fold increase in dispensing efficiency through technological upgrades. This operational momentum is further bolstered by strategic partnerships, such as the one with Independent Gyms, which provides access to the MedPal Wellness app for over 2,000 gyms, and the partnership with Epassi UK, which allows access to over 11 million employees at major firms.

MedPal AI's current market capitalisation stands at approximately £8 million, reflecting its growth trajectory since its AIM admission. The company has raised a total of £4.54 million in funding, which, considering its operational burn rate, provides a runway of approximately 12 months. The recent capital raises, however, introduce dilution risk, particularly as the company continues to expand its operations and pursue additional growth initiatives. The financial position appears stable for the time being, but ongoing capital requirements will need to be monitored closely, especially as the company scales its operations and seeks to enhance its market presence.

In terms of valuation, MedPal AI's enterprise value is currently difficult to ascertain given its early-stage revenue generation. However, it is essential to compare it with direct peers in the digital health and pharmacy services sector. Notable peers include AIM: HEMO and AIM: CLLN, which have market capitalisations of approximately £10 million and £12 million, respectively. While MedPal AI's revenue generation is still nascent, its monthly pharmacy revenue of £350,000 translates to an annualised run rate of £4.2 million. This suggests a potential forward EV/Revenue multiple that could be competitive if growth continues at the current pace. In contrast, HEMO and CLLN have established revenue streams, which could provide a more stable valuation benchmark for investors.

The execution record of MedPal AI has been aggressive, with management successfully meeting several key milestones since its AIM listing. The rapid establishment of the National Distribution Centre and the launch of the MedPal.clinic website indicate a strong operational focus. However, the company faces specific risks, particularly in terms of regulatory compliance and market competition. The approval from the Norfolk and Waveney Integrated Care Board for the pharmacy licence change is a positive development, but ongoing regulatory scrutiny in the healthcare sector could pose challenges as the company scales. Additionally, the reliance on technological infrastructure for its AI-driven services introduces operational risks, particularly in maintaining service quality and efficiency.

Looking ahead, the next measurable catalyst for MedPal AI is the anticipated growth in user adoption of the MedPal Wellness app, which has already seen 7,791 installs. The company aims to leverage its partnerships to drive further engagement, with a target of expanding its user base significantly over the coming months. The rollout across Epassi UK's network is expected to enhance visibility and user acquisition, potentially leading to increased pharmacy revenues. This growth trajectory will be critical for sustaining investor confidence and justifying the current market valuation.

In conclusion, MedPal AI's announcement reflects a significant step in its evolution from a pre-revenue company to a fully operational digital health platform. The transition is marked by substantial operational milestones and a growing revenue stream, albeit from a low base. The announcement is classified as significant due to the operational developments and funding achievements that position the company for future growth, though it remains to be seen how effectively it can navigate the associated risks and maintain momentum in a competitive landscape.